[go: up one dir, main page]

MX2018008545A - Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana. - Google Patents

Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana.

Info

Publication number
MX2018008545A
MX2018008545A MX2018008545A MX2018008545A MX2018008545A MX 2018008545 A MX2018008545 A MX 2018008545A MX 2018008545 A MX2018008545 A MX 2018008545A MX 2018008545 A MX2018008545 A MX 2018008545A MX 2018008545 A MX2018008545 A MX 2018008545A
Authority
MX
Mexico
Prior art keywords
antibacterial composition
staphylococcal infections
antibacterial
treating staphylococcal
seq
Prior art date
Application number
MX2018008545A
Other languages
English (en)
Other versions
MX394323B (es
Inventor
Youn Jun Soo
Hyeon KANG Sang
Jun Yoon Seong
Mo Jung Gi
Original Assignee
Intron Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intron Biotechnology Inc filed Critical Intron Biotechnology Inc
Publication of MX2018008545A publication Critical patent/MX2018008545A/es
Publication of MX394323B publication Critical patent/MX394323B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un método para tratar infecciones por estafilococos que incluye administrar a un sujeto una cantidad eficaz de una composición antibacteriana que tiene una amplia actividad bactericida. La composición antibacteriana incluye una primera proteína antibacteriana que consiste en la secuencia aminoacídica como se expone en la SEQ. ID. NO:1 y/o una segunda proteína antibacteriana que consiste en la secuencia aminoacídica como se expone en la SEQ. ID. NO:2.
MX2018008545A 2016-01-12 2017-01-09 Uso de una composición antibacteriana para tratar infecciones por estafilococos. MX394323B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277506P 2016-01-12 2016-01-12
PCT/IB2017/050087 WO2017122111A1 (en) 2016-01-12 2017-01-09 An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition

Publications (2)

Publication Number Publication Date
MX2018008545A true MX2018008545A (es) 2018-12-19
MX394323B MX394323B (es) 2025-03-24

Family

ID=59310874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008545A MX394323B (es) 2016-01-12 2017-01-09 Uso de una composición antibacteriana para tratar infecciones por estafilococos.

Country Status (15)

Country Link
US (1) US11229677B2 (es)
EP (1) EP3402506A4 (es)
JP (1) JP7085483B2 (es)
KR (1) KR102669340B1 (es)
CN (1) CN109414478B (es)
AU (1) AU2017208114B2 (es)
BR (1) BR112018014175A2 (es)
CA (1) CA3010564C (es)
MX (1) MX394323B (es)
MY (1) MY199203A (es)
RU (2) RU2707738C1 (es)
SG (1) SG11201811479RA (es)
UA (2) UA128879C2 (es)
WO (1) WO2017122111A1 (es)
ZA (1) ZA201804013B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN111235119B (zh) * 2020-03-05 2021-11-23 苏州十一方生物科技有限公司 一种融合抗菌蛋白的制备及应用
CN112402591B (zh) * 2020-11-23 2022-12-16 中国农业科学院饲料研究所 防御素dlp4在治疗仔猪渗出性皮炎中的应用
KR102426421B1 (ko) * 2021-01-06 2022-07-29 주식회사 리신바이오 신규 재조합 엔도라이신 및 이의 용도
KR102739428B1 (ko) * 2022-07-26 2024-12-11 주식회사 인트론바이오테크놀로지 황색포도알균을 포함한 포도알균에 대하여 강력한 용균 활성을 갖는 항균단백질

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
US9603909B2 (en) * 2012-05-29 2017-03-28 Intron Biotechnology, Inc. Composition capable of improving stability of bacteriophage lysin proteins
RU2734308C2 (ru) * 2016-01-12 2020-10-15 Интрон Байотекнолоджи, Инк. Лиофилизированные композиции антибактериального белка

Also Published As

Publication number Publication date
CA3010564A1 (en) 2017-07-20
BR112018014175A2 (en) 2018-12-26
UA126022C2 (uk) 2022-08-03
US11229677B2 (en) 2022-01-25
US20190282657A1 (en) 2019-09-19
AU2017208114A1 (en) 2018-07-26
RU2729934C2 (ru) 2020-08-13
RU2707738C1 (ru) 2019-11-29
MX394323B (es) 2025-03-24
KR20180114010A (ko) 2018-10-17
ZA201804013B (en) 2019-07-31
CN109414478B (zh) 2022-08-23
CA3010564C (en) 2024-01-30
CN109414478A (zh) 2019-03-01
RU2019136978A (ru) 2019-12-19
AU2017208114B2 (en) 2023-04-13
EP3402506A1 (en) 2018-11-21
KR102669340B1 (ko) 2024-05-28
SG11201811479RA (en) 2019-01-30
JP2019503379A (ja) 2019-02-07
RU2019136978A3 (es) 2020-04-02
JP7085483B2 (ja) 2022-06-16
UA128879C2 (uk) 2024-11-13
EP3402506A4 (en) 2019-09-04
MY199203A (en) 2023-10-19
WO2017122111A1 (en) 2017-07-20
NZ749842A (en) 2024-11-29

Similar Documents

Publication Publication Date Title
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
MY199203A (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
EP4349360A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
WO2018115140A3 (en) Virulence attenuated bacteria based protein delivery
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
MY200975A (en) "Compositions Comprising Amino acids for use in the Treatment of Mitochondrial Dysfunction-Related Diseases"
MX369056B (es) Prevención, interrupción y tratamiento de biopelículas con lisina de bacteriófago.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
WO2017176807A9 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
MX2019006768A (es) Peptidos antimicrobianos.
EA201991501A1 (ru) Противомикробная композиция, содержащая олигодинамический металл
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
PH12018500358A1 (en) Compounds for use in an antibacterial applications
JP2013539776A5 (es)
WO2015075062A3 (en) Method of treating hair
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2020001084A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
MX373912B (es) Terapias antibioticas peptidicas derivadas del bufalo de agua
MY187334A (en) Xylanase